Ken Griffin Atai Life Sciences N.V. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 103,400 shares of ATAI stock, worth $168,542. This represents 0.0% of its overall portfolio holdings.
Number of Shares
103,400
Previous 257,000
59.77%
Holding current value
$168,542
Previous $341,000
58.94%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ATAI
# of Institutions
98Shares Held
23.7MCall Options Held
351KPut Options Held
170K-
Ubs Group Ag5.54MShares$9.02 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.29MShares$5.37 Million0.0% of portfolio
-
Pale Fire Capital Se Prague, 2N2.59MShares$4.23 Million0.42% of portfolio
-
Davidson Kempner Capital Management LP New York, NY1.41MShares$2.3 Million0.07% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$2.13 Million0.0% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $270M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...